Literature DB >> 9990360

Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells.

A M Jensen1, M B Lladó, L Skov, E R Hansen, J K Larsen, O Baadsgaard.   

Abstract

The aim of this study was to elucidate some of the possible mechanisms of action of the vitamin D analogue calcipotriol in vivo. Calcipotriol is finding increasing use in the treatment of psoriasis, but the primary target cell in vivo has not yet been identified. We treated psoriatic patients and healthy volunteers with calcipotriol and placebo ointment for 4 and 7 days, and obtained epidermal cell suspensions from treated areas. Epidermal cells were cocultured with autologous T cells, isolated from peripheral blood, in the absence or the presence of a classical antigen or a superantigen. In both psoriatic and normal skin, calcipotriol treatment did not alter the capacity of epidermal antigen-presenting cells to stimulate the proliferation of autologous T cells, either in the absence or in the presence of exogenous antigen. Epidermal cell suspensions were analysed further by staining for infiltrating leucocytes (CD45+) and Langerhans cells (CD1a+). Flow cytometric analysis showed that calcipotriol did not alter the number of CD45+ cells or Langerhans cells in psoriatic skin. These results indicate that calcipotriol does not alter either the number of the function of epidermal antigen-presenting cells in psoriatic epidermis. In contrast, we found that calcipotriol significantly inhibited the proliferation of epidermal cells isolated from psoriatic skin after in vivo treatment, as determined by propidium iodide staining and flow cytometry. More specifically, we stained for CD29+ keratinocytes and found an even more significant reduction in proliferative capacity. This cell type contains the population of hyperproliferative keratinocytes in psoriatic epidermis. In conclusion, calcipotriol seems to act via an inhibitory effect on hyperproliferative basal keratinocytes of psoriatic epidermis, rather than via an effect on infiltrating leucocytes, including antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9990360     DOI: 10.1046/j.1365-2133.1998.02553.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

Review 1.  [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review].

Authors:  M A Radtke; K Herberger; T Kornek; M Augustin
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

2.  Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.

Authors:  Nicoletta Cassano; Antonio Miracapillo; Carmela Coviello; Francesco Loconsole; Marco Bellino; Gino Antonio Vena
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin.

Authors:  Mohammad Alhadj Ali; Sally L Thrower; Stephanie J Hanna; Sion A Coulman; James C Birchall; F Susan Wong; Colin Mark Dayan; Danijela Tatovic
Journal:  Immunology       Date:  2015-09-13       Impact factor: 7.397

4.  Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model.

Authors:  Peter H Kvist; Lars Svensson; Oskar Hagberg; Vibeke Hoffmann; Kaare Kemp; Mads A Røpke
Journal:  J Transl Med       Date:  2009-12-17       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.